Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Laurus Global Equity Management Inc.

Laurus Global Equity Management Inc. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,180 shares of the medical research company's stock after buying an additional 11,030 shares during the period. Charles River Laboratories International comprises 9.1% of Laurus Global Equity Management Inc.'s investment portfolio, making the stock its 3rd largest position. Laurus Global Equity Management Inc. owned 0.18% of Charles River Laboratories International worth $13,574,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Rothschild Investment LLC increased its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the period. Optiver Holding B.V. purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $37,000. HM Payson & Co. purchased a new position in Charles River Laboratories International in the 1st quarter worth approximately $31,000. GeoWealth Management LLC increased its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after purchasing an additional 190 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $48,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of several research analyst reports. Evercore ISI boosted their target price on Charles River Laboratories International from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their target price for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $174.54.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 2.3%

Shares of NYSE:CRL traded down $3.68 on Tuesday, reaching $154.36. The company had a trading volume of 542,550 shares, compared to its average volume of 1,030,581. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The firm's 50 day simple moving average is $144.87 and its 200-day simple moving average is $151.35. The firm has a market capitalization of $7.58 billion, a PE ratio of -237.48, a PEG ratio of 5.40 and a beta of 1.49. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.27 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).